Terms: = Lymphoma AND GOPC, FIG, 57120, ENSG00000047932, GOPC1, Q9HD26, CAL, dJ94G16_2 PIST AND Treatment
50 results:
1. Colonic infiltration of chronic lymphocytic leukemia with Hodgkin Reed Sternberg-like cells.
Nova-Camacho LM; Val-Carreres Castellote A; Riego Repullo V
Rev Esp Enferm Dig; 2022 Aug; 114(8):510-511. PubMed ID: 35297262
[TBL] [Abstract] [Full Text] [Related]
2. Diffuse Large B-Cell lymphoma.
Sehn LH; Salles G
N Engl J Med; 2021 Mar; 384(9):842-858. PubMed ID: 33657296
[TBL] [Abstract] [Full Text] [Related]
3. Approved and emerging PI3K inhibitors for the treatment of chronic lymphocytic leukemia and non-Hodgkin lymphoma.
Kienle DL; Stilgenbauer S
Expert Opin Pharmacother; 2020 Jun; 21(8):917-929. PubMed ID: 32162560
[TBL] [Abstract] [Full Text] [Related]
4. Role of prophylactic radiotherapy in Chinese patients with primary testicular diffuse large B-cell lymphoma: a single retrospective study.
Xu J; Ke Y; Zhang Y; Chen C; Li J; Wei Z; Liu P
J BUON; 2019; 24(2):754-762. PubMed ID: 31128033
[TBL] [Abstract] [Full Text] [Related]
5. Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.
Sang AX; McPherson MC; Ivison GT; Qu X; Rigdon J; Esquivel CO; Krams SM; Martinez OM
Am J Transplant; 2019 May; 19(5):1305-1314. PubMed ID: 30549430
[TBL] [Abstract] [Full Text] [Related]
6. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract] [Full Text] [Related]
7. Combined effects of aspirin and vitamin D3 on two OSCC cell lines: a preliminary study.
Xiao TT; Li X; Feng JL; Li Y
Biotechnol Lett; 2018 Mar; 40(3):551-559. PubMed ID: 29349624
[TBL] [Abstract] [Full Text] [Related]
8. PI3Kδ activates E2F1 synthesis in response to mRNA translation stress.
Gnanasundram SV; Pyndiah S; Daskalogianni C; Armfield K; Nylander K; Wilson JB; Fåhraeus R
Nat Commun; 2017 Dec; 8(1):2103. PubMed ID: 29235459
[TBL] [Abstract] [Full Text] [Related]
9. [Progress on treatment of Splenic Marginal Zone lymphoma-Review].
Wu L; Tian C; Zhang YZ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):600-603. PubMed ID: 28446319
[TBL] [Abstract] [Full Text] [Related]
10. Suppression of B-cell development genes is key to glucocorticoid efficacy in treatment of acute lymphoblastic leukemia.
Kruth KA; Fang M; Shelton DN; Abu-Halawa O; Mahling R; Yang H; Weissman JS; Loh ML; Müschen M; Tasian SK; Bassik MC; Kampmann M; Pufall MA
Blood; 2017 Jun; 129(22):3000-3008. PubMed ID: 28424165
[TBL] [Abstract] [Full Text] [Related]
11. A p110δ-specific inhibitor combined with bortezomib blocks drug resistance properties of EBV-related B cell origin cancer cells via regulation of NF-κB.
Park GB; Chung YH; Jeong JY; Kim D
Int J Oncol; 2017 May; 50(5):1711-1720. PubMed ID: 28339079
[TBL] [Abstract] [Full Text] [Related]
12. PI3K-δ inhibition using cal-101 exerts apoptotic effects and increases doxorubicin-induced cell death in pre-B-acute lymphoblastic leukemia cells.
Safaroghli-Azar A; Bashash D; Sadreazami P; Momeny M; Ghaffari SH
Anticancer Drugs; 2017 Apr; 28(4):436-445. PubMed ID: 28125433
[TBL] [Abstract] [Full Text] [Related]
13. Suberoyl bis-hydroxamic acid activates Notch1 signaling and induces apoptosis in anaplastic thyroid carcinoma through p53.
Li J; Zheng X; Gao M; Zhao J; Li Y; Meng X; Qian B; Li J
Oncol Rep; 2017 Jan; 37(1):458-464. PubMed ID: 28004113
[TBL] [Abstract] [Full Text] [Related]
14. Indication for liver transplantation in a patient with a history of a gastric lymphoma.
Ruiz Pardo J; Cascales Campos PA; Parrilla Paricio P
Rev Esp Enferm Dig; 2016 Jun; 108(6):379. PubMed ID: 26937630
[TBL] [Abstract] [Full Text] [Related]
15. [Effects of the phosphoinostitide-3'-kinase delta inhibitor, cal-101, in combination with Bortezomib on mantle lymophma cells and exploration of its related mechanism].
Qu F; Xia B; Li X; Guo S; Zhang L; Tian C; Yu Y; Zhang Y
Zhonghua Zhong Liu Za Zhi; 2015 Jun; 37(6):412-7. PubMed ID: 26463142
[TBL] [Abstract] [Full Text] [Related]
16. CD30 As a Target for the treatment of Cutaneous T-Cell lymphoma.
Prince HM
J Clin Oncol; 2015 Nov; 33(32):3691-6. PubMed ID: 26392103
[TBL] [Abstract] [Full Text] [Related]
17. Idelalisib for relapsed/refractory indolent B-cell non-Hodgkin's lymphoma: an overview of pharmacokinetics and clinical trial outcomes.
Davies A
Expert Rev Hematol; 2015 Oct; 8(5):581-93. PubMed ID: 26343890
[TBL] [Abstract] [Full Text] [Related]
18. The influence of rituximab, high-dose therapy followed by autologous stem cell transplantation, and age in patients with primary CNS lymphoma.
Madle M; Krämer I; Lehners N; Schwarzbich M; Wuchter P; Herfarth K; Egerer G; Ho AD; Witzens-Harig M
Ann Hematol; 2015 Nov; 94(11):1853-7. PubMed ID: 26268792
[TBL] [Abstract] [Full Text] [Related]
19. Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisib.
Maffei R; Fiorcari S; Martinelli S; Potenza L; Luppi M; Marasca R
J Hematol Oncol; 2015 May; 8():60. PubMed ID: 26022368
[TBL] [Abstract] [Full Text] [Related]
20. Combining cal-101 with Celecoxib Enhances Apoptosis of EBV-transformed B-Cells Through MAPK-induced ER Stress.
Park GB; Hur DY; Kim D
Anticancer Res; 2015 May; 35(5):2699-708. PubMed ID: 25964548
[TBL] [Abstract] [Full Text] [Related]
[Next]
